TP53 and non-small cell lung carcinoma: Mukhopadhyay and Roth initially showed the feasibility of p53 gene therapy in 1993, by transferring the WT p53 gene into the H322a cell line (human non-small cell lung cancer (NSCLC)), in order to examine the role of the WT and mutated p53 genes during cell growth and tumorigenesis [7].